|Videos|November 17, 2021

CAR T-Cell Therapies, Antibody-Specific Therapies Are in the Pipeline for Multiple Myeloma

Pharmacists should keep an eye on the pipeline for autologous and allogeneic CAR T-cell therapies as well as antibody-specific treatments.

Several important drug classes are being investigated for use in the treatment of multiple myeloma, according to Jeff Pohler, RPh, senior director of precision medicine at Alliance Rx Walgreens Prime.

In an interview with Pharmacy Times®, Pohler said pharmacists should keep an eye on the pipeline for autologous and allogeneic CAR T-cell therapies as well as antibody-specific treatments. In addition, Pohler discussed how the COVID-19 pandemic impacted treatment for multiple myeloma and how pharmacists can monitor patients with more treatments moving into the home environment.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME

$Managing Steroid-Refractory Chronic Graft-versus-Host Disease With Novel Therapies: Opportunities for Pharmacist-Led Interventions$

CAR T-Cell Therapies, Antibody-Specific Therapies Are in the Pipeline for Multiple Myeloma

Related Content

Cardiovascular Inflammation Persists in Some Patients With CVD Despite Standard Treatment

COVID-19 Boosters May Offer Head Start Against Future Animal Coronaviruses, But Immune "Imprinting" Complicates the Picture

Heal or Harm: Body Protective Compound-157 in the Gray Zone

Opioid Stewardship in Acute Pain Care Must Go Beyond Prescription Reduction

Family-Based Therapy Shows Superior Weight Gain in Children With ARFID, Landmark Trial Finds

Latest CME

Managing Steroid-Refractory Chronic Graft-versus-Host Disease With Novel Therapies: Opportunities for Pharmacist-Led Interventions

Advances in Castration-Sensitive Prostate Cancer: A Pharmacist's Approach to Optimize Novel Antiandrogen Therapies

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape

Breast Cancer Day of Education 2026

Neuropsychiatry Day of Education 2026

Adapting to Advances in EGFR-Positive Non-Small Cell Lung Cancer Treatment: Critical Insights for Oncology Pharmacists

Securing the Supply Chain: The Pharmacists’ Role in DSCSA Compliance

Expanding the Role of Long-Acting Injectables in Optimizing Schizophrenia Management

Breaking Barriers in Asthma Care: Exploring the Role of Type 2 Inflammation and Biologic Therapies

Addressing the Burden of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: The Pharmacist's Contribution to Patient Care

Lymphoma Day of Education 2026

Exploring Oncolytic Viruses in Melanoma: Pharmacist-Led Approaches for Safe Integration

Biomarker Testing in Practice: Navigating Modalities and Multidisciplinary Decision-Making

Outsmart the Algorithm: Combatting Misinformation at the Pharmacy Counter

Translating KDIGO Updates and Clinical Evidence Into Managed Care Decision-Making in IgA Nephropathy

Innovations in Retinal Therapies: A Managed Care Perspective on Anti-VEGF Advancements

Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations

Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Lymphomas: A Practical Guide for Pharmacists

Targeting the Complement Cascade: Evolving Strategies in the Management of Complement-Mediated Kidney Diseases

Continuing the Conversation: Pharmacist Interventions to Optimize T2D Care and Break Through Clinical Inertia

Personalizing Treatment in Relapsed/Refractory Multiple Myeloma: The Evolving Role of Antibody-Drug Conjugates and Bispecific Antibodies

Pharmacists at the Forefront: Enhancing Immunotherapy Strategies in Endometrial Cancer

Breast Cancer Day of Education 2026

Neuropsychiatry Day of Education 2026

VMAT2 Inhibitors for Long-Term Success in Tardive Dyskinesia

Shifting Perspectives in Treatment-Resistant Depression: Novel Therapies and Patient-Centered Care

Navigating Adverse Effects in HR+/HER2-Negative Metastatic Breast Cancer: Tailored Management Plans and Pharmacist Interventions for Improved Outcomes

Optimizing Therapy in HR+/HER2-Negative Metastatic Breast Cancer: Navigating Novel Treatments and Personalized Care

Bridging Knowledge Gaps in HR+/HER2– Early-Stage Breast Cancer

Optimizing HER2-Directed Therapy in Metastatic Breast Cancer: From HER2-Positive to HER2-Ultralow

From Flares to Freedom: Navigating the Journey of Patients With Chronic Spontaneous Urticaria With Next-Generation Therapies

Shaping the Future of Generalized Myasthenia Gravis Management: A Focus on Novel Treatment Approaches

Expert Insights on the Horizon of HER2-Directed Therapy

Type 2 Inflammation in Focus: Advancing Pediatric Atopic Dermatitis Care With Biologic Therapies

Understanding Type 2 Inflammation and Its Role Across Various Immune-Related Diseases

Chronic Obstructive Pulmonary Disease and Inflammation: Practical Approaches to Integrating Biologic Therapy

Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies

Updated Guidance and Managed Care Strategies to Optimize Care in EGFR Mutated NSCLC

Payment for Pharmacist Services: 2025 Update

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

The Oncology Pharmacist's Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enhance Patient-Centered Care

Lymphoma Day of Education 2026

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

Paroxysmal Nocturnal Hemoglobinuria: Managed Care Strategies to Mitigate Burden and Enhance Outcomes

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

The Pharmacist's Role in Palliative and End of Life Symptom Management

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

Clinical Presentation of Hyperglycemia with PI3K and AKT Inhibitors

Reducing the Treatment Burden in HIV Management: The Pharmacist’s Role in Long-Acting Injectable Adoption

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

Optimizing Lipid Management in Statin-Intolerant Populations: Payer Strategies for Evidence-Based Access and Risk Reduction

Addressing Vaccine Hesitancy in Infectious Disease Prevention

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

The Expanding Therapeutic Landscape in IgA Nephropathy: Translating New Clinical Evidence and Updated Guidelines Into Managed Care Strategies

From Guidelines to Action: Implementing Pneumococcal Vaccine ACIP Recommendations in Long-Term Care Settings